Drug Profile

IO 112

Alternative Names: 1O-112; Arginase-1 peptide vaccine - IO Biotech; IO112

Latest Information Update: 11 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator IO Biotech
Developer Herlev Hospital; IO Biotech; Zealand University Hospital
Class Cancer vaccines; Peptide vaccines
Mechanism of Action Cytotoxic T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Myeloproliferative disorders
No development reported Solid tumours

Most Recent Events

04 Feb 2025 Pharmacodynamics data from preclinical trial in Cancer released by IO Biotech
07 Nov 2024 Pharmacodynamics data from preclinical trial in Solid tumours released by IO Biotech
07 Nov 2024 IO Biotech plans to submit an IND application for IO 112 in Solid tumours in 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com